Guerbet S. A. (GBT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Guerbet S. A. (GBT) has a cash flow conversion efficiency ratio of 0.188x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€48.81 Million ≈ $57.07 Million USD) by net assets (€260.08 Million ≈ $304.06 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see GBT market cap overview for the company's overall valuation and market capitalisation.
Guerbet S. A. - Cash Flow Conversion Efficiency Trend (2004–2025)
This chart illustrates how Guerbet S. A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Guerbet S. A. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Guerbet S. A. ranked by their cash flow conversion efficiency. Explore GBT cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shinsegae Food
KO:031440
|
-0.062x |
|
Papoutsanis S.A
AT:PAP
|
0.086x |
|
Neo Technical System Co. Ltd
KQ:085910
|
0.035x |
|
Cardiff Oncology Inc
NASDAQ:CRDF
|
-0.131x |
|
Phoenix Group Holdings PLC
LSE:PHNX
|
4.726x |
|
Cheryong Industrial Co.Ltd
KQ:147830
|
0.085x |
|
Getty Images Holdings Inc.
NYSE:GETY
|
0.067x |
|
Cemacon Zalau
RO:CEON
|
N/A |
Annual Cash Flow Conversion Efficiency for Guerbet S. A. (2004–2025)
The table below shows the annual cash flow conversion efficiency of Guerbet S. A. from 2004 to 2025. View Guerbet S. A. (GBT) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €260.08 Million ≈ $304.06 Million |
€61.29 Million ≈ $71.66 Million |
0.236x | +13.62% |
| 2024-12-31 | €391.57 Million ≈ $457.79 Million |
€81.22 Million ≈ $94.95 Million |
0.207x | +185.97% |
| 2023-12-31 | €378.27 Million ≈ $442.24 Million |
€27.44 Million ≈ $32.08 Million |
0.073x | -9.56% |
| 2022-12-31 | €379.57 Million ≈ $443.76 Million |
€30.44 Million ≈ $35.59 Million |
0.080x | -71.99% |
| 2021-12-31 | €405.09 Million ≈ $473.60 Million |
€115.97 Million ≈ $135.58 Million |
0.286x | -12.58% |
| 2020-12-31 | €367.75 Million ≈ $429.94 Million |
€120.43 Million ≈ $140.80 Million |
0.327x | -2.91% |
| 2019-12-31 | €389.19 Million ≈ $455.01 Million |
€131.27 Million ≈ $153.47 Million |
0.337x | +60.82% |
| 2018-12-31 | €366.76 Million ≈ $428.78 Million |
€76.92 Million ≈ $89.93 Million |
0.210x | +28.02% |
| 2017-12-31 | €342.14 Million ≈ $400.00 Million |
€56.05 Million ≈ $65.53 Million |
0.164x | +33.31% |
| 2016-12-31 | €314.80 Million ≈ $368.03 Million |
€38.69 Million ≈ $45.23 Million |
0.123x | -47.13% |
| 2015-12-31 | €282.44 Million ≈ $330.20 Million |
€65.65 Million ≈ $76.75 Million |
0.232x | +0.42% |
| 2014-12-31 | €259.10 Million ≈ $302.92 Million |
€59.98 Million ≈ $70.12 Million |
0.231x | -6.97% |
| 2013-12-31 | €238.26 Million ≈ $278.55 Million |
€59.28 Million ≈ $69.30 Million |
0.249x | +26.10% |
| 2012-12-31 | €226.21 Million ≈ $264.46 Million |
€44.63 Million ≈ $52.18 Million |
0.197x | +2.26% |
| 2011-12-31 | €214.80 Million ≈ $251.12 Million |
€41.44 Million ≈ $48.45 Million |
0.193x | +9.66% |
| 2010-12-31 | €210.52 Million ≈ $246.12 Million |
€37.04 Million ≈ $43.30 Million |
0.176x | -2.95% |
| 2009-12-31 | €205.31 Million ≈ $240.02 Million |
€37.22 Million ≈ $43.51 Million |
0.181x | +6.39% |
| 2008-12-31 | €185.73 Million ≈ $217.13 Million |
€31.65 Million ≈ $37.00 Million |
0.170x | -27.70% |
| 2007-12-31 | €170.96 Million ≈ $199.86 Million |
€40.29 Million ≈ $47.11 Million |
0.236x | +244.21% |
| 2006-12-31 | €152.14 Million ≈ $177.86 Million |
€10.42 Million ≈ $12.18 Million |
0.068x | -76.90% |
| 2005-12-31 | €141.16 Million ≈ $165.03 Million |
€41.84 Million ≈ $48.92 Million |
0.296x | +10.90% |
| 2004-12-31 | €120.21 Million ≈ $140.54 Million |
€32.13 Million ≈ $37.56 Million |
0.267x | -- |
About Guerbet S. A.
Guerbet SA provides a range of contrast media, medical devices, and digital and AI solutions for diagnostic and interventional imaging worldwide. It offers DOTAREM, a macrocyclic gadolinium-based contrast agent for use in contrast-enhanced MRI examinations; Elucirem, a macrocyclic gadolinium-based contrast agent for use in contrast-enhanced resonance imaging; UNIK, a diagnostic imaging interconne… Read more